BRD4592A is a synthetic azetidine derivative discovered by whole cell screening that kills Mycobacterium tuberculosis (Mtb) through allosteric inhibition of tryptophan synthase (TrpAB). It binds at the TrpAB a–b-subunit interface and affects multiple steps in the enzyme’s overall reaction resulting in bactericidal activity.  It is active in zebrafish, but has metabolic liabilities including rapid mouse liver microsome clearance that preclude its efficacy testing in a mouse model.  The Mtb TrpAB gene is essential in vivo.

From Sutherland et al. 2019 abstract:

Whole-cell based high-throughput screen with aerobically grown Mtb H37Rv. MIC = 0.125 - 0.25 ug/ml  From Abstract:  Used "structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure−activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in serum inhibition titration assays."